1. Home
  2. BAK vs OCS Comparison

BAK vs OCS Comparison

Compare BAK & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Braskem SA ADR

BAK

Braskem SA ADR

HOLD

Current Price

$1.96

Market Cap

900.6M

Sector

Industrials

ML Signal

HOLD

Logo Oculis Holding AG Ordinary shares

OCS

Oculis Holding AG Ordinary shares

N/A

Current Price

$13.09

Market Cap

732.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BAK
OCS
Founded
1972
2003
Country
Brazil
Switzerland
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
900.6M
732.4M
IPO Year
2002
2022

Fundamental Metrics

Financial Performance
Metric
BAK
OCS
Price
$1.96
$13.09
Analyst Decision
Hold
Strong Buy
Analyst Count
2
6
Target Price
$4.40
$42.00
AVG Volume (30 Days)
1.8M
247.9K
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$16.02
$466.06
Revenue Next Year
$7.04
$479.73
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.83
$10.52
52 Week High
$5.40
$34.48

Technical Indicators

Market Signals
Indicator
BAK
OCS
Relative Strength Index (RSI) 32.95 55.11
Support Level $1.83 $10.63
Resistance Level $3.17 $13.28
Average True Range (ATR) 0.15 0.52
MACD -0.00 0.20
Stochastic Oscillator 17.47 69.15

Price Performance

Historical Comparison
BAK
OCS

About BAK Braskem SA ADR

Braskem SA is engaged in the manufacture, sale, import and export of chemicals, petrochemicals and fuels, as well as the production, supply and sale of utilities such as steam, water, compressed air and industrial gases. It also provides industrial services and is engaged in the production, supply and sale of electric energy and gas for its own use and use by other companies. Its segments include Brazil, USA and Europe; and Mexico. The Brazil segments delivered the majority of the revenue from the production and sale of chemicals; the supply of electricity and other inputs produced in these complexes to second-generation producers located in the petrochemical complexes; and the production and sale of PE, including the production of green PE made from renewable resources, and of PP.

About OCS Oculis Holding AG Ordinary shares

Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.

Share on Social Networks: